SpringSoft Agrees to Acquire Certess
Addition of unique functional qualification technology strengthens SpringSoft’s verification enhancement portfolio and expands customer access to Certitude product
SpringSoft Agrees to Acquire Certess
SpringSoft, Inc. (TAIEX: 2473), a global supplier of specialized IC design software, today announced that it has signed a definitive agreement to acquire all the outstanding shares of Certess, Inc., creators of the Certitude™ Functional Qualification solution. Pending customary shareholder and regulatory approvals, Certess will become a wholly owned subsidiary of SpringSoft USA, Inc. and its operations will be integrated with SpringSoft’s global development, sales, support and marketing functions.
In 2008, SpringSoft merged with Novas Software, Inc. and three other companies in which it had invested to create a global EDA company specializing in unique automation technologies that save engineers time. The Certess acquisition expands the range of verification solutions offered by SpringSoft with the industry’s first commercial functional qualification software product. Certess products will be added to SpringSoft’s Novas™ family of verification enhancement solutions.
“Certess is one of the hot start-ups in the Intelligent Test Bench market. This acquisition by SpringSoft significantly strengthens their technology portfolio, positioning them well for a shot at becoming one of the major EDA vendors in the new world of Electronic Design Automation,” said Gary Smith, Chief Analyst at Gary Smith EDA.
Certess employs 20 people primarily in France and the United States. SpringSoft will retain Certess’s entire R&D operation in France, which will report to Yu-Chin Hsu, Vice President of Logic Verification R&D, and will fold the Certess field sales and support personnel into its global channel. Certess CEO Michel Courtoy will stay with the company in a non-executive consulting role. In this capacity, he will help ensure a smooth integration process and rapid roll-out of the Certitude product to the SpringSoft sales and support channel.
“At this challenging time for the entire EDA ecosystem, users need to be more productive than ever and vendors need to provide more value,” said Martin Lu, CEO of SpringSoft. “This acquisition reinforces our specialization strategy and brings another high-value automation solution to the SpringSoft user community to address their pain in reaching verification closure. The Certess technology is a natural fit with our existing verification enhancement product line, and the synergy between our organizations will enable us to further accelerate SpringSoft’s growth in the global EDA market.”
“The combination of Certess with SpringSoft is a win for customers, employees and investors,” said Michel Courtoy, CEO of Certess. “Over the last couple of years, the Certitude Functional Qualification solution has enjoyed rapid adoption by key semiconductor companies. SpringSoft’s verification enhancement strategy and global resources will ensure that the widest possible range of users can take advantage of this unique technology.”
Verification Enhancement
Verification enhancement technologies make it easier for engineers to do more verification in less time, to more easily understand and correct design behavior, and to improve the quality of verification environments so they can attain higher levels of confidence in their system-on-chip (SoC) designs.
SpringSoft is the only EDA vendor specializing in verification enhancement technologies and solutions. The company’s Verdi™ Automated Debug and Siloti™ Visibility Automation solutions work side by side with third-party simulators using industry-standard languages and interfaces to improve design comprehension and productivity throughout the functional verification process. The integration of Certess functional qualification technologies, which interoperate with simulators in the same way, will enable SpringSoft users to ensure the thoroughness of their verification environments to achieve functional closure faster with more reliable quality of results.
About Certess
Certess, Inc. is the only electronic design automation company providing functional qualification products for companies that create and integrate complex design blocks for systems on a chip (SoCs) or intellectual property (IP). The company’s technology provides design and verification engineers with an objective way to evaluate and improve the completeness of the verification environment, resulting in a shorter and more predictable process to integrate SoC designs and ensure high quality designs. The company is headquartered in Campbell, CA. For additional information, see www.certess.com .
About SpringSoft
SpringSoft, Inc. is a global supplier of specialized automation technologies that accelerate engineers during the design, verification and debug of complex digital, analog and mixed-signal ICs, ASICs, microprocessors, and SoCs. Its award-winning product portfolio features the Novas Verification Enhancement and Laker Custom IC Design solutions used by more than 400 of today's leading IDM and fabless semiconductor companies, foundries, and electronic systems OEMs. Headquartered in Hsinchu, Taiwan, and San Jose, California, SpringSoft is the largest company in Asia specializing in IC design software and a recognized industry leader in customer service with more than 400 employees located in multiple R&D sites and local support offices around the world. For more information, visit www.springsoft.com .
Verdi and Siloti are trademarks of SpringSoft, Inc. Certitude is a trademark of Certess, Inc. All other trademarks or registered trademarks are the property of their respective owners.
Contact:
For SpringSoft:
Investor Relations:
Sam Wu, +886-3-579-4567
ext. 257
sam_wu@springsoft.com
or
Media
Relations:
Rob van Blommestein, +1-408-467-7872
rob_vanblommestein@springsoft.com
or
For
Certess:
Media Relations:
Michelle Clancy,
+1
252-940-0981
Michelle.clancy@cayennecom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom